NEWS & MEDIA

IPEM, the only international private equity and venture capital marketplace has selected StemTek to attend its 3rd event at Cannes from the 24th to the 26th of January. IPEM offers an innovative format with private spaces and lounges to conduct appointments and facilitate productive meetings, along a conferences and workshops program and networking events designed to engender the exchange of ideas, experiences and viewpoints.    

Stemtek, one of the most powerful 50 entrepreneurs start ups

StemTek is proud to be among those 50 selected companies. - June 12, 2017

“Emprendedores”magazine with the help of the best experts in the matter has analyzed over 200 new projects in Spain: business idea, innovation, growth potential, team… and made a list of the most powerful 50 entrepreneurs start ups that are meant to succeed. StemTek is proud to be among those 50 selected companies. > Download this article here  

Emprendedores magazine wrote about StemTek Therapeutics (ES)

Emprendedores magazine wrote about StemTek Ready-to-use 3D Cell Culture Kit. - June 05, 2017

     

El Correo newspaper wrote about StemTek Therapeutics

El Correo newspaper wrote about StemTek Therapeutics in their Innovation section. - June 05, 2017

El Correo newspaper wrote about StemTek Therapeutics in their Innovation section, showing the work being carried out at StemTek to help discover the next generation of cancer-fighting drugs and our recent participation in the MassChallenge program in Boston. > Download this article here  

A new dimension

Biology is not flat, so one expert in the sector is aiming to make 3D cell culture a commodity, explains Angel Garcia Martin. - June 02, 2017

Biology is not flat, so one expert in the sector is aiming to make 3D cell culture a commodity, explains Angel Garcia Martin. > Download this article in .pdf Pharma companies realise that most of the pre-clinical testing they have been doing just isn’t good enough. As many as 9 in 10 drug candidates fail in clinical testing, and the majority of this attrition is due to toxicity and efficacy issues. This suggests that the translational tools currently used for predicting efficac...
Downloads
Back to top